Royal Hospital Chelsea

Recent publications and citations

Top Concepts

Top subject area publications in last 5 years

Collaboration Analysis

Publications from 2021 to 2026

Latest Publications

Filter IconFilter

Showing 10 of 22 papers

  • Open Access
  • Research Article

269P Performance of publicly available large language models as decision-aids for lung cancer screening: An evaluation of quality, safety, and readability

  • Nov 01, 2025
  • ESMO Real World Data and Digital Oncology
  • S Khanna +4
  • Research Article

510P Clinical and molecular characteristics of cancers that switch phenotype from ER+ primary to triple negative in metastatic disease

  • Sep 01, 2025
  • Annals of Oncology
  • L Morrison +15
  • Research Article

1700eTiP SCOPE phase II clinical trial program evaluating off-the-shelf DNA plasmid vaccines, SCIB1 and iSCIB1+ administered in combination with checkpoint inhibitors in advanced unresectable melanoma

  • Sep 01, 2025
  • Annals of Oncology
  • N Varawalla +19
  • Research Article

1517MO Emerging survival plateaus with botensilimab and balstilimab: Pan tumor data from a large phase Ib trial of advanced solid tumors

  • Sep 01, 2025
  • Annals of Oncology
  • M Gordon +15
  • Research Article

109O Capturing clonal evolution through histology

  • Sep 01, 2025
  • Annals of Oncology
  • C Spencer +19
  • Open Access
  • Research Article

1166P Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/GOG-3024/ENGOT-cx8 study

  • Sep 01, 2025
  • Annals of Oncology
  • B.j Monk +19
  • Open Access
  • Research Article

65MO Clinicopathological risk score following neoadjuvant imatinib predicts relapse-free survival in patients with GIST

  • Mar 01, 2025
  • ESMO Open
  • J Pozas +13
  • Open Access
  • Research Article

58MO Advancing salivary gland cancer research: A multidisciplinary approach to addressing the unmet clinical need

  • Mar 01, 2025
  • ESMO Open
  • R Metcalf +18
  • Open Access
  • Research Article
  • Citations1

190P: Real-world 5-year survival outcomes with durvalumab (D) after chemoradiotherapy (CRT) in unresectable, stage III NSCLC (urNSCLC): Final data extraction from PACIFIC-R

  • Mar 01, 2025
  • Journal of Thoracic Oncology
  • N Girard +19
  • Open Access
  • Abstract

1852P The use of patient-reported outcome measures to assess toxicities and quality of life associated with immune checkpoint inhibitor therapy: A systematic review

  • Sep 01, 2024
  • Annals of Oncology
  • P.p Jaganathan +6
Cactus Communications logo

Copyright 2026 Cactus Communications. All rights reserved.